Catalyst Pharmaceuticals (CPRX) Stock
Specialty drug company focused on rare neuromuscular diseases. Here's the price, business snapshot, and what's worth knowing about Catalyst Pharmaceuticals in September 2026.
Catalyst Pharmaceuticals (CPRX) is a US-based specialty biopharmaceutical company focused on therapies for rare neuromuscular and other orphan diseases. Its revenue to date has largely been driven by sales of its lead product for a specific neuromuscular disorder, with future growth depending on label expansions, new approvals and international launches. Investors should note the typical small-cap biotech profile: potential for step‑change upside from regulatory successes, balanced by execution, regulatory, patent and market-concentration risks. Financials can be variable and the share price may react strongly to clinical, commercial or legal news. This summary is for general educational purposes only and not personal investment advice. Consider your risk tolerance, time horizon and seek independent financial or tax advice before acting. Past performance is not a guide to the future and returns are not guaranteed.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts strongly recommend buying Catalyst Pharmaceuticals' stock due to its promising future value.
Financial Health
Catalyst Pharmaceuticals is performing well with strong profits and cash flow, indicating financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Revenue Concentration
Sales are currently driven by a small number of products; this can mean rapid upside from launches but also high sensitivity to setbacks.
Regulatory Catalysts
Approvals, label expansions or international launches can materially affect valuation, though outcomes are uncertain and timing can vary.
Orphan Market Dynamics
Targeting rare diseases can offer premium pricing and patient loyalty, yet commercial scale is limited and healthcare policy changes can impact access.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
